Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13593325 | 1.00 | POLB (0.55) | POLBALDH1A1TDP1GAAALOX15 | |
| SCHEMBL5655283 | 0.98 | POLB (0.56) | POLBALDH1A1TDP1GAAALOX15 | |
| SCHEMBL31661644 | 0.98 | POLB (0.56) | POLBALDH1A1TDP1GAAALOX15 | |
| SCHEMBL3046406 | 0.90 | POLB (0.69) | POLBALDH1A1TDP1GAAALOX15 | |
| SCHEMBL31661769 | 0.90 | POLB (0.69) | POLBALDH1A1TDP1GAAALOX15 | |
| SCHEMBL7717051 | 0.90 | POLB (0.69) | POLBALDH1A1TDP1GAAALOX15 | |
| SCHEMBL5656576 | 0.90 | POLB (0.69) | POLBALDH1A1TDP1GAAALOX15 | |
| SCHEMBL7718043 | 0.90 | POLB (0.69) | POLBALDH1A1TDP1GAAALOX15 | |
| SCHEMBL7719057 | 0.85 | POLB (0.71) | POLBALDH1A1TDP1GAAALOX15 | |
| SCHEMBL7718038 | 0.82 | GAA (0.74) | POLBTDP1GAAKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090324540-A1 | COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | EMISPHERE TECHNOLOGIES, INC. (US) | 2009-12-31 | — | — | US | disclosed |
| US-20090324540-A1 | COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | EMISPHERE TECHNOLOGIES, INC. (US) | 2009-12-31 | — | — | US | disclosed |
| US-7553872-B2 | Compounds and compositions for delivering active agents | EMISPHERE TECHNOLOGIES, INC. (US) | 2009-06-30 | — | — | US | disclosed |
| US-7553872-B2 | Compounds and compositions for delivering active agents | EMISPHERE TECHNOLOGIES, INC. (US) | 2009-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090324540-A1 | COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | ABCB4, ABCB7, ALPP | POLB 1332/4885ALDH1A1 1939/4885TDP1 3031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.